1. MAPK/ERK Pathway
  2. p38 MAPK

SB 202190 

Cat. No.: HY-10295 Purity: 99.12%
Handling Instructions

SB 202190 inhibits p38 and p38β2 with IC50 values of 50 nM and 100 nM. respectively.

For research use only. We do not sell to patients.
SB 202190 Chemical Structure

SB 202190 Chemical Structure

CAS No. : 152121-30-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
50 mg USD 60 In-stock
100 mg USD 106 In-stock
200 mg USD 198 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

    SB 202190 purchased from MCE. Usage Cited in: J Neuroinflammation. 2017 Nov 25;14(1):228.

    HSP70 release induced by morphine is reversed by ERK1/2 inhibitor in SH-SY5Y cells. SCH772984 (ERK1/2 inhibitor, 2 μM) is given 15 min before Morphine (200 μM, 12 h) administration. Supernatants are collected and analyzed by western blot (n=3).

    SB 202190 purchased from MCE. Usage Cited in: EBioMedicine. 2015 Nov 19;2(12):1944-56.

    SW620 xenograft tumors are treated with SB202190 and OSI027 individually or in combination. The effect on signaling by p38 (P-MK2 and P-Hsp27) and mTOR (P-S6K1 and P-AKT) is analyzed by immunoblot. SB202190 achieves on-target inhibition by diminishes phosphorylation of MK2 and Hsp27. OSI-027 blocks signaling by both mTORC1 and mTORC2 by decreases phosphorylation of S6K1 and AKT. When SB202190 and OSI-027 are used in combination, all three kinases, p38, mTORC1 and mTORC2 are potently inhibited.

    SB 202190 purchased from MCE. Usage Cited in: Int J Mol Med. 2017 Jan;39(1):71-80.

    Inhibition of c-Jun N-terminal kinase (JNK) expression enhances the promoting effects of miR-214 on adipocyte differentiation and decreases p-JNK protein expression in bone marrow-derived mesenchymal stem cells (BMSCs) following the overexpression of miR-214. p-JNK protein expression is even more significantly suppressed by treatment of the cells with JNK inhibitor as shown by (A) western blot analysis and (B) statistical analysis of p-JNK protein expression.

    SB 202190 purchased from MCE. Usage Cited in: Int J Mol Med. 2017 Jan;39(1):71-80.

    Inhibition of p38 expression enhances the promoting effect of miR-214 on the adipocyte differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) following the overexpression of miR-214. p-p38 protein expression decreases following treatment with p38 inhibitor, as shown by (A) western blot analysis, and (B) statistical analysis of p-p38 protein expression.

    SB 202190 purchased from MCE. Usage Cited in: Oxid Med Cell Longev. 2017;2017:7426458.

    Representative immunoblot analysis of p53, p16, p21, and retinoblastoma protein (Rb) in NP cells.

    SB 202190 purchased from MCE. Usage Cited in: China Biotechnology. 2017, 37(12): 40-48.

    The Western blot analysis of HOG1 and Phospho-HOG1.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    SB 202190 inhibits p38 and p38β2 with IC50 values of 50 nM and 100 nM. respectively.

    IC50 & Target

    IC50: 50 nM (p38), 100 nM (p38β2)[1]

    In Vitro

    Treatment of cells with SB 202190 (SB202190) significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner as measured in immune complex kinase assays with GST-hsp27 as a substrate. Jurkat cells are treated with SB202190 or left untreated. After 24 h, cells are harvested, and the activity of CPP32-like caspases in cell extracts is measured by cleavage of the fluorescent peptide DEVD-AMC, which is a specific substrate of CPP32-like caspases. The cleavage of DEVD-AMC is significantly increased in cells treated with SB202190 but not in the control[2].

    In Vivo

    In HCT-116-derived colorectal tumors, administration of SB 202190 (SB202190), Sorafenib or a combination of both give similar results in terms of measurement of external tumor size (around 58% growth reduction compare with control tumors). SB202190 induces a 28% reduction of tumor growth, compare with a 31% reduction promoted by Sorafenib, while combination of both drugs reduce tumor growth by 55%[3]. Compare to the model group, the SB202190 group exhibits significantly shorter escape latencies in the Morris water maze hidden platform trials (P<0.01) and longer times in the original platform quadrant during probe trials (P<0.01). The SB202190 group also shows significantly reduced neuronal apoptosis in the hippocampus compared to VaD model rats (P<0.01) as well as higher (antiapoptotic) Bcl-2 expression and lower (proapoptotic) caspase-3 expression (P<0.01 for both). In conclusion, blockade of the p38 MAPK signaling pathway by SB202190 following permanent 2-OV reduced apoptosis of hippocampal neurons and rescued spatial learning and memory deficits[4].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 3.0180 mL 15.0902 mL 30.1805 mL
    5 mM 0.6036 mL 3.0180 mL 6.0361 mL
    10 mM 0.3018 mL 1.5090 mL 3.0180 mL
    Please refer to the solubility information to select the appropriate solvent.
    Kinase Assay

    MAPKAPK 2 assays are performed. Briefly, Jurkat cells are serum-starved for 24 h and then incubated with or without the specific p38 inhibitor SB 202190 for 30 min prior to treatment with anti-Fas mAb (100 ng/mL) for 2 h or left alone as indicated in the figure legends. The cells are harvested in lysis buffer and clarified by centrifugation. Endogenous MAPKAPK 2 is immunoprecipitated with anti-MAPKAPK 2 polyclonal antibody for 3 h at 4°C. The activity of the immune complex is assayed at 30°C for 30 min in 30 μL of kinase buffer in the presence of 1 μM ATP/10 μCi [γ-32P]ATP (10 Ci/mmol) with GST-hsp27 as a substrate. The reactions are terminated with Laemmli sample buffer. The proteins are resolved by 13% SDS-polyacrylamide gel electrophoresis followed by autoradiography. The phosphorylated proteins are quantitated by a PhosphorImager[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay

    SB 202190 (SB202190) is dissolved in DMSO and stored, and then diluted with appropriate media before use[2].

    Jurkat/neo or Jurkat/bcl-2 cells (106 cells) are treated with or without SB202190 (50 μM), PD098059 (50 μM) in the presence or absence of caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp (zVAD)-fluoromethylketone for 24 h. The cells are then harvested in lysis buffer (25 mM Hepes, pH 7.4, 0.25% Nonidet P-40, 10 μg/mL leupeptin, 10 μg/mL aprotinin, 5 mM EDTA, 2 mM dithiothreitol, and 10 mM digitonin). The lysates are clarified by centrifugation, and the supernatants are used for caspase assays. The caspase activity is measured in a reaction mixture containing 20 μg of cell extracts, 20 μM fluoregenic peptide acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin (DEVD-AMC). Fluorescent AMC product formation is measured at excitation 360 nm, emission 460 nm using a Cytofluor II fluorescent plate reader[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    SB 202190 (SB202190) is dissolved in 100% DMSO and diluted in normal saline for a final concentration of DMSO of 0.1% (Rats)[4].

    Female CD-1 athymic nude mice (6-8 week old) are used. 10×106 HT-29 or 10×106 HCT-116 cells are injected subcutaneously into the flanks (0.2 mL per flank) of female athymic nude CD-1 mice. The volume of the tumors is measured every 2-3 d. The tumor volume is calculated using the following formula: volume (mm3)=(width)2×length×0.5. When the tumor volume reaches 60 mm3, mice are randomized into four treatment groups (n≥6 for each group): vehicle (control), Sorafenib 30 mg/kg/d, SB202190 25 μg/kg/d, and Sorafenib 30 mg/kg/d plus SB202190 25 μg/kg/d. Drug treatment is given daily by gavage for Sorafenib and intraperitoneally for SB202190. Mice are treated for 12 d and tumor volume and body weight are recorded every 2-3 d. At the end of the treatment, mice are sacrificed and tumors explanted for histologic and immunohistochemical analysis.
    Specific pathogen-free (SPF) male Wistar rats (3 month old, 250±10 g) are used. The 60 Wistar rats are randomly assigned to the sham-operated group, the VaD model group, and the SB 202190 group (20 animals each) using a random number table. The VaD rat model (n=40) is established by separating and ligating the bilateral carotid artery via two-vessel occlusion (2-VO). For animals of the sham-operated group (n=20), the bilateral carotid artery is separated using the same methods but without ligation. After recovery, animals of the SB 202190 group receive intracerebroventricular (ICV) injection of SB 202190 and both the VaD model and sham-operated groups received ICV injection of equal volume 0.1% DMSO. In each group, eight rats are examined in the Morris water maze to assess spatial learning and memory, six rats are sacrificed and brain sections are prepared for TUNEL staining and Bcl-2/caspase-3 immunohistochemistry, and six rats are sacrificed and tissue homogenates are prepared for Western blot assay of phospho-p38 MAPK expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only.


    Purity: 99.12%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    SB 202190
    Cat. No.: